Euro vs US Dollar

Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.

Registrieren

ITCI Intra Cellular Therapies Inc

127,08

0,08 (0,06%)

01 Feb 2025 - Geschlossen

Verzögert um 15 Minuten

Form 144 - Report of proposed sale of securities

="/Images/box-checked.jpg" alt="Checkbox checked">

144: Remarks and Signature

Remarks

Date of Notice

09/06/2024

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

/s/ Marc Binda

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

Intra Cellular Therapies (NASDAQ:ITCI)
Historical Stock Chart
Von Jan 2025 bis Feb 2025

Click Here for more Intra Cellular Therapies Charts.

Intra Cellular Therapies (NASDAQ:ITCI)
Historical Stock Chart
Von Feb 2024 bis Feb 2025

Click Here for more Intra Cellular Therapies Charts.

News Intra Cellular Therapies Inc

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Montag 13 Januar 2025 (3 Wochen vor) • Edgar (US Regulatory)

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Montag 13 Januar 2025 (3 Wochen vor) • Edgar (US Regulatory)

Form 8-K - Current report
Montag 13 Januar 2025 (3 Wochen vor) • Edgar (US Regulatory)

Johnson & Johnson Strengthens Neuroscience Leadership with Acquisition of Intra-Cellular Therapies, Inc.
Montag 13 Januar 2025 (3 Wochen vor) • GlobeNewswire Inc.

Johnson & Johnson Strengthens Neuroscience Leadership with Acquisition of Intra-Cellular Therapies, Inc.
Montag 13 Januar 2025 (3 Wochen vor) • Business Wire

Form 8-K - Current report
Freitag 10 Januar 2025 (3 Wochen vor) • Edgar (US Regulatory)

Intra-Cellular Therapies Settles CAPLYTA® (lumateperone) Patent Litigation with Sandoz
Freitag 10 Januar 2025 (3 Wochen vor) • GlobeNewswire Inc.

Intra-Cellular Therapies to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Montag 6 Januar 2025 (4 Wochen vor) • GlobeNewswire Inc.

Intra-Cellular Therapies Presents Data from the CAPLYTA Adjunctive MDD Phase 3 Program at the American College of Neuropsychopharmacology Annual Meeting
Mittwoch 11 Dezember 2024 (2 Monate vor) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
Samstag 7 Dezember 2024 (2 Monate vor) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Donnerstag 5 Dezember 2024 (2 Monate vor) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Mittwoch 4 Dezember 2024 (2 Monate vor) • Edgar (US Regulatory)

Weitere Intra Cellular Therapies Inc News-Artikel

Euro vs Sterling

Deutsche Telekom (QX)

Deutsche Lufthansa

Invesco QQQ Trust Series 1

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen